Therapeutic banner
Therapeutic banner

Transthyretin (ATTR) Amyloidosis

View the latest scientific data presented at congress events in the past 2 years and discover peer-reviewed publications related to ATTR Amyloidosis.
The information on this page pertains to select congress and publication resources. It is not intended to serve as a comprehensive list of all congress and publications resources.

Explore Therapeutic Areas

Publications

View More Arrow

Transthyretin Amyloidosis (ATTR)

DISCOVERY: prevalence of transthyretin (TTR) mutations in a US-centric patient population suspected of having cardiac amyloidosis

Amyloid

Author(s)

Ola Akinboboye, Keyur Shah, Alberta L. Warner, et al.

May 2020

Transthyretin Amyloidosis (ATTR)

Patisiran Pharmacokinetics, Pharmacodynamics, and Exposure-Response Analyses in the Phase 3 APOLLO Trial in Patients With Hereditary Transthyretin-Mediated (hATTR) Amyloidosis

Journal of Clinical Pharmacology

Author(s)

Xiaoping Zhang, Varun Goel, Husain Attarwala, et al

July 2019

Transthyretin Amyloidosis (ATTR)

Association of Patisiran, an RNA Interference Therapeutic, With Regional Left Ventricular Myocardial Strain in Hereditary Transthyretin Amyloidosis: The APOLLO Study

JAMA Cardiology

Author(s)

Masatoshi Minamisawa, Brian Claggett, David Adams, et al

March 2019

Transthyretin Amyloidosis (ATTR)

Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis

Circulation

Author(s)

Scott Solomon, David Adams, Arnt Kristen, et al

January 2019

Transthyretin Amyloidosis (ATTR)

Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis

New England Journal of Medicine

Author(s)

David Adams, Alejandra Gonzalez-Duarte, William O’Riordan, et al

July 2018